1. Academic Validation
  2. CD2 Immunobiology

CD2 Immunobiology

  • Front Immunol. 2020 Jun 9:11:1090. doi: 10.3389/fimmu.2020.01090.
Christian Binder 1 2 Filip Cvetkovski 2 Felix Sellberg 1 2 Stefan Berg 2 Horacio Paternina Visbal 1 2 David H Sachs 2 3 Erik Berglund 2 4 David Berglund 1 2
Affiliations

Affiliations

  • 1 Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden.
  • 2 Research and Development, ITB-Med AB, Stockholm, Sweden.
  • 3 Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, United States.
  • 4 Division of Transplantation Surgery, CLINTEC, Karolinska Institute, and Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden.
Abstract

The glycoprotein CD2 is a costimulatory receptor expressed mainly on T and NK cells that binds to LFA3, a cell surface protein expressed on e.g., antigen-presenting cells. CD2 has an important role in the formation and organization of the immunological synapse that is formed between T cells and antigen-presenting cells upon cell-cell conjugation and associated intracellular signaling. CD2 expression is upregulated on memory T cells as well as activated T cells and plays an important role in activation of memory T cells despite the coexistence of several Other costimulatory pathways. Anti-CD2 monoclonal Antibodies have been shown to induce immune modulatory effects in vitro and clinical studies have proven the safety and efficacy of CD2-targeting biologics. Investigators have highlighted that the lack of attention to the CD2/LFA3 costimulatory pathway is a missed opportunity. Overall, CD2 is an attractive target for monoclonal Antibodies intended for treatment of pathologies characterized by undesired T cell activation and offers an avenue to more selectively target memory T cells while favoring immune regulation.

Keywords

Alefacept; CD2; CD58; LFA-3 (lymphocyte functional antigen-3); T cell activation; costimulation; costimulation blockade; siplizumab.

Figures